[go: up one dir, main page]

WO2003044039A3 - Atrial natriuretic peptide clearance receptor variant associated with bone disorders - Google Patents

Atrial natriuretic peptide clearance receptor variant associated with bone disorders Download PDF

Info

Publication number
WO2003044039A3
WO2003044039A3 PCT/US2002/036858 US0236858W WO03044039A3 WO 2003044039 A3 WO2003044039 A3 WO 2003044039A3 US 0236858 W US0236858 W US 0236858W WO 03044039 A3 WO03044039 A3 WO 03044039A3
Authority
WO
WIPO (PCT)
Prior art keywords
natriuretic peptide
atrial natriuretic
bone disorders
receptor variant
variant associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/036858
Other languages
French (fr)
Other versions
WO2003044039A2 (en
Inventor
Neelam Jaiswal
Adam Houghton
Lawrence Mertz
Darren Ji
Jonathan S Cook
Douglas W Axelrod
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ore Pharmaceuticals Inc
Procter and Gamble Co
Original Assignee
Ore Pharmaceuticals Inc
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ore Pharmaceuticals Inc, Procter and Gamble Co filed Critical Ore Pharmaceuticals Inc
Priority to AU2002346423A priority Critical patent/AU2002346423A1/en
Publication of WO2003044039A2 publication Critical patent/WO2003044039A2/en
Publication of WO2003044039A3 publication Critical patent/WO2003044039A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to identifying genes that are differentially regulated or expressed in bone deposition disorders. Specifically, a novel gene variant has been identified as being differentially regulated during the maturation of osteoblasts and whose expression can be correlated, for example, with bone deposition disorders such as osteoporosis.
PCT/US2002/036858 2001-11-16 2002-11-18 Atrial natriuretic peptide clearance receptor variant associated with bone disorders Ceased WO2003044039A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002346423A AU2002346423A1 (en) 2001-11-16 2002-11-18 Atrial natriuretic peptide clearance receptor variant associated with bone disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33144601P 2001-11-16 2001-11-16
US60/331,446 2001-11-16

Publications (2)

Publication Number Publication Date
WO2003044039A2 WO2003044039A2 (en) 2003-05-30
WO2003044039A3 true WO2003044039A3 (en) 2003-12-11

Family

ID=23294005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036858 Ceased WO2003044039A2 (en) 2001-11-16 2002-11-18 Atrial natriuretic peptide clearance receptor variant associated with bone disorders

Country Status (2)

Country Link
AU (1) AU2002346423A1 (en)
WO (1) WO2003044039A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070118295A1 (en) * 2005-03-02 2007-05-24 Al-Murrani Samer Waleed Khedhe Methods and Systems for Designing Animal Food Compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] DOE JOINT GENOME INSTITUTE AND STANFORD HUMAN GENOME CENTER; 12 July 2001 (2001-07-12), XP002968522, Database accession no. (AC026703) *
DATABASE GENBANK [online] DOE JOINT GENOME INSTITUTE; 18 July 2000 (2000-07-18), XP002968523, Database accession no. (AC026751) *
DATABASE GENBANK [online] LOWE D.G. ET AL.: "cDNA sequence of the human atrial natriuretic peptide clearance receptor", XP002968524, Database accession no. (X52282) *
NUCLEIC ACID RESEARCH, vol. 18, no. 11, 1990, pages 3412 *

Also Published As

Publication number Publication date
AU2002346423A8 (en) 2003-06-10
AU2002346423A1 (en) 2003-06-10
WO2003044039A2 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
WO2005027962A3 (en) 4’-thionucleosides and oligomeric compounds
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
WO2004044132A3 (en) Modified oligonucleotides for use in rna interference
WO2004072100A3 (en) Nell peptide expression systems and bone formation activity of nell peptide
WO2004033659A3 (en) Novel tumor suppressor gene and compositions and methods for making and using the same
WO2006090391A3 (en) System and method for computerized ordering among replaceable or otherwise associated products
AU2433901A (en) Chimeric natriuretic peptides
MXPA03007983A (en) Process for the preparation of middle distillates.
EP1345482A3 (en) Frame member for electrical distribution cabinets
WO2005044976A3 (en) Oligomeric compounds for use in gene modulation
ZA200200179B (en) Process for upgrading of Fischer-Tropsch products.
WO2004043882A3 (en) Highly homogeneous amorphous silica-alumina catalyst composition
IL135688A0 (en) Human checkpoint kinase, hcds1, compositions and methods
WO2003046205A3 (en) Methods for identifying modulators of apoptosis
WO2003012070A3 (en) Gene associated with bone disorders
WO2003057843A3 (en) Methods and materials for modulating trpc4
WO2003044039A3 (en) Atrial natriuretic peptide clearance receptor variant associated with bone disorders
WO2003057847A3 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
MX2008004899A (en) Compounds and methods for peptide ribonucleic acid condensate particles for rna therapeutics.
WO2005045020A3 (en) Enzymatic synthesis, modification and decomposition of silicon(iv) compounds and other metal(iv) compounds
EP0885964A3 (en) Method for cloning and producing the BssHII restriction endonuclease in E.coli
WO2002068380A8 (en) Synthetic excitatory amino acids
AU2003285485A1 (en) 5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
WO2004050834A3 (en) GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
ZA200408272B (en) Compositions for improving the flavor of alcoholicbeverage made from grape.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP